Brukinsa (Zanubrutinib) Patent Expiration, LOE Window & CMS Spending

Brukinsa (Zanubrutinib) by BeiGene / BeOne Medicines: FDA Orange Book core substance LOE 2037-08-15 (last listed 2043-01-19), 0 AB generics, $1.77B 2024 CMS Part D & Medicaid spend, and $15,744 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorBeiGene / BeOne Medicines
FDA Application & PathwayN218785 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2037-08-15
Last Listed Patent or Exclusivity Date2043-01-19
Orange Book Patents (*PED Extensions)13 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$1.77B
2024 Medicare Part D Spend$1.72B
2024 Medicaid Spend$47.1M
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($15,744 intro WAC)